{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rosch JW"],"funding":["NIAID NIH HHS","NIDCD NIH HHS","NIGMS NIH HHS"],"pagination":["141-54"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3936495"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but "],"journal":["EMBO molecular medicine"],"pubmed_title":["A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media."],"pmcid":["PMC3936495"],"funding_grant_id":["R01 AI027913","RC1DC010566","RC1 DC010566","T32 GM008169","T32 AI007401"],"pubmed_authors":["Humann J","Murrah KA","Perez AC","Tuomanen EI","Rosch JW","Edward Swords W","Mann B","Vogel P","Gao G","McCullers JA","Iverson AR","Mina M"],"additional_accession":[]},"is_claimable":false,"name":"A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media.","description":"Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but ","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jan","modification":"2025-05-18T12:47:20.079Z","creation":"2025-05-18T12:47:20.079Z"},"accession":"S-EPMC3936495","cross_references":{"pubmed":["24408968"],"doi":["10.1002/emmm.201202150"]}}